Italian hedge fund BxWorld Fund has entered a position in Soligenix (Nasdaq: SNGX), a biotech company with some interesting products for the cure of cancer and a range of products against bioterrorism and radioactive warfare. Luca Fer, BxWorld’s fund manager, says: “We consider the company a target also for the USA government or some defense institution”. We think that the target price is $11.00.

Soligenix  is an interesting stock at present. Now trading with a market value of just $16.07M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Soligenix Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For SNGX, the company currently has $7.14 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has $8.41 million in total assets, balanced by $2.59 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Soligenix, Inc. saw -$1.63 million in free cash flow last quarter, representing a quarterly net change in cash of -$1.63 million. Perhaps most importantly where cash movements are concerned, the company saw about -$1.63 million in net operating cash flow.

Soligenix Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw $1.33 million in total revenues. That represents a quarterly year/year change in revenues of -0.49 in sequential terms, SGNX saw sales decline by -0.22.